Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-05-01 00:00:00 ET · period of report 2023-04-27 · accession 0001209191-23-026270 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-05-01 | 2023-04-27 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $339.08 | -3,317 | 126.7K | -3% | -$1.12M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-27 | S | D | 38 | $340.19 | 126,652 | D | — | — | |
| 2 | Common | Common Stock | 2023-04-27 | S | D | 1,611 | $338.69 | 128,358 | D | — | — | (F3) Open market sales reported on this line occurred at a weighted average price of $338.69 (range $338.00 to $338.99). (F2) Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2023-04-27 | S | D | 1,668 | $339.43 | 126,690 | D | — | — | (F4) Open market sales reported on this line occurred at a weighted average price of $339.43 (range $339.00 to $339.98). (F2) Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |